Neurofibromatosis Type 1
Neurofibromatosis Type 1 (NF1) is a genetic disorder with no cure and limited treatment options. It affects many parts of the body, most notably causing benign tumors that grow on or around nerves. These tumors can lead to pain, nerve damage, and other complications as they grow. People with NF1 also face an increased risk of developing certain cancers, including malignant peripheral nerve sheath tumors, brain tumors, and breast cancer, reducing life expectancy by an estimated 10 to 15 years. NF1 can also cause cognitive challenges, bone deformities, and heart problems.
SPARC convened experts from the neurofibromatosis research community, various biomedical disciplines, patient foundations, and the pharmaceutical industry to discuss the state of the science of NF and barriers to research progress. The resulting discussions were critical to identifying the key unmet needs and philanthropic opportunities to advance NF research and patient outcomes.
Our Work
Neurofibromatosis Type 1: A Giving Smarter Guide
SPARC evaluated the NF1 research and funding landscape to identify where philanthropic investment could have the greatest impact. The resulting Giving Smarter Guide helps patients, supporters, and other stakeholders understand the state of the science and make informed decisions about where to direct their philanthropic support.
Scientific Priorities
Experts in the field prioritized the following opportunities to address unmet needs in NF research:
Standardized clinical care
Developing and implementing national evidence-based clinical care guidelines supported by a coordinated network of NF specialists would standardize treatment, improve outcomes, and create the infrastructure needed for clinical research.
Access to patient biospecimens
Creating a centralized system with standardized protocols for collecting and storing NF patient biospecimens would provide researchers with high-quality samples needed to advance understanding and develop new treatments.
Biomarkers
Validating existing NF biomarkers and supporting new biomarker research through focused initiatives would improve diagnosis, track disease progression, and measure treatment response.
Understanding the disease biology
Focused research programs addressing disease biology, genetic factors, and tumor microenvironment interactions are needed to accelerate the discovery of new therapies.
Fresh research agendas
Investing in high-risk, high-reward research programs focused on gene therapy, stem cell therapy, and advanced disease modeling could unlock transformative treatments for NF.
Commercial development framework
Establishing management teams with business and legal expertise and creating a central hub to facilitate partnerships and intellectual property agreements would accelerate the development of NF treatments.